go-v.orgdoi

Treating pediatric osteosarcoma: recent clinical trial evidence

Alexandra K Abrams, Raffi S. Avedian, Neyssa M. Marina · Clinical Investigation · 2013

  • DOI 10.4155/cli.13.89
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2013

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2013

Abstract

Pediatric osteosarcoma is most commonly diagnosed during adolescence and young adulthood and requires treatment with surgical intervention and intensive chemotherapy. While the exact molecular mechanism leading to osteosarcoma has yet to be elucidated, some syndromes and genetic conditions have been associated with development of the disease. Treatment of osteosarcoma has always included surgical intervention with amputation being most common prior to the introduction of multi-agent chemotherapy. The introduction of multi-agent chemotherapy along with improved surgical techniques have allowed increasing use of limb-salvage surgery.

Current investigations including the use of modern chemotherapy show no detectable survival difference between amputation and limb salvage surgery. Standard neo-adjuvant and adjuvant regimens using a combination of doxorubicin, cisplatin and methotrexate, with or without ifosfamide have become the standard in the medical management of osteosarcoma. Other newer agents, such as HER2 receptor monoclonal antibody and muramyl tripeptide phosphatidylethanolamine have also been investigated and are included in this review.

Open the resolved locator · 10.4155/cli.13.89

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 23:04 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.13.89
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.